Adrienne Waks, MD

Trials

Studies that name Adrienne Waks, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:46 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT06876714 · ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

  Alliance for Clinical Trials in Oncology · recruiting · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer · study chair
• Ph2
  NCT06100874 · A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

  Adrienne G. Waks · active not recruiting · Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic · principal investigator
• Ph2
  NCT04425018 · MARGetuximab Or Trastuzumab (MARGOT)

  Dana-Farber Cancer Institute · active not recruiting · Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer · principal investigator
• Ph2
  NCT03414658 · The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

  Adrienne G. Waks · active not recruiting · Breast Cancer · principal investigator
• Ph2
  NCT02326974 · T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

  Dana-Farber Cancer Institute · active not recruiting · HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.